Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 308

1.

Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.

Mulligan MJ, Stapleton JT, Keitel WA, Frey SE, Chen WH, Rouphael N, Edupuganti S, Beck A, Winokur PL, El Sahly HM, Patel SM, Atmar RL, Graham I, Anderson E, El-Kamary SS, Pasetti MF, Sztein MB, Hill H, Goll JB; DMID 08-0006 Tularemia Vaccine Study Group.

Vaccine. 2017 Aug 24;35(36):4730-4737. doi: 10.1016/j.vaccine.2017.07.024. Epub 2017 Jul 24.

2.

[Rheumatologist with heart and soul : On the death of Wolfgang Müller].

Keitel W.

Z Rheumatol. 2017 Aug;76(6):554-555. doi: 10.1007/s00393-017-0339-8. German. No abstract available.

PMID:
28707125
3.

Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.

Jackson LA, Frey SE, El Sahly HM, Mulligan MJ, Winokur PL, Kotloff KL, Campbell JD, Atmar RL, Graham I, Anderson EJ, Anderson EL, Patel SM, Fields C, Keitel W, Rouphael N, Hill H, Goll JB.

Vaccine. 2017 Mar 23;35(13):1675-1682. doi: 10.1016/j.vaccine.2017.02.032. Epub 2017 Feb 27.

PMID:
28256358
4.

Challenges Remain for Influenza Vaccination of Children.

Edwards KM, Keitel WA.

J Infect Dis. 2016 Nov 15;214(10):1470-1472. Epub 2016 Aug 28. No abstract available.

PMID:
27571903
5.

Max Hirsch (1875-1941): His forgotten fate and his contributions to the founding of modern rheumatology.

Keitel W, Olsson L, Matteson EL.

Eur J Rheumatol. 2016 Sep;3(3):101-105. Epub 2016 Sep 1.

6.

Progress toward the Development of a NEAT Protein Vaccine for Anthrax Disease.

Balderas MA, Nguyen CT, Terwilliger A, Keitel WA, Iniguez A, Torres R, Palacios F, Goulding CW, Maresso AW.

Infect Immun. 2016 Nov 18;84(12):3408-3422. Print 2016 Dec.

7.

[Kurt Seidel (1914-1990) : Between medicine and politics].

Keitel W, Wolf G.

Z Rheumatol. 2016 Sep;75(7):736-42. doi: 10.1007/s00393-016-0162-7. German.

PMID:
27488445
8.

Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.

Feldstein LR, Matrajt L, Elizabeth Halloran M, Keitel WA, Longini IM Jr; H5N1 Vaccine Working Group.

Vaccine. 2016 Jul 19;34(33):3796-802. doi: 10.1016/j.vaccine.2016.05.067. Epub 2016 Jun 20.

9.

Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans.

Quinn CP, Sabourin CL, Schiffer JM, Niemuth NA, Semenova VA, Li H, Rudge TL, Brys AM, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Parker SD, Babcock J, Keitel W, Poland GA, Keyserling HL, El Sahly H, Jacobson RM, Marano N, Plikaytis BD, Wright JG.

Clin Vaccine Immunol. 2016 Apr 4;23(4):326-38. doi: 10.1128/CVI.00696-15. Print 2016 Apr.

10.

Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.

Mbawuike IN, Atmar RL, Patel SM, Corry DB, Winokur PL, Brady RC, Chen WH, Edwards KM, Creech CB, Walter EB Jr, Frey SE, Belshe RB, Goll JB, Hill H, Keitel WA.

Vaccine. 2016 Jan 20;34(4):547-554. doi: 10.1016/j.vaccine.2015.11.055. Epub 2015 Dec 4.

11.

[Originators and eponyms of dermatomyositis : Ernst Leberecht Wagner (1821-1888) and Heinrich Unverricht (1853-1912)].

Keitel W, Wolff HP.

Z Rheumatol. 2016 May;75(4):429-34. doi: 10.1007/s00393-015-0008-8. German.

PMID:
26589202
12.

Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant.

Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL.

Clin Vaccine Immunol. 2015 Nov 11;23(1):73-7. doi: 10.1128/CVI.00475-15.

13.

Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here?

Atmar RL, Keitel WA.

J Infect Dis. 2016 Apr 15;213(8):1211-3. doi: 10.1093/infdis/jiv459. Epub 2015 Oct 28. No abstract available.

PMID:
26516140
14.

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.

Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech CB, Thomsen IP, Patel SM, Gutierrez AF, Anderson EL, El Sahly HM, Hill H, Noah DL, Bellamy AR.

JAMA. 2015 Jul 21;314(3):237-46. doi: 10.1001/jama.2015.7916.

PMID:
26197184
15.

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.

Frey SE, Wald A, Edupuganti S, Jackson LA, Stapleton JT, El Sahly H, El-Kamary SS, Edwards K, Keyserling H, Winokur P, Keitel W, Hill H, Goll JB, Anderson EL, Graham IL, Johnston C, Mulligan M, Rouphael N, Atmar R, Patel S, Chen W, Kotloff K, Creech CB, Chaplin P, Belshe RB.

Vaccine. 2015 Sep 22;33(39):5225-34. doi: 10.1016/j.vaccine.2015.06.075. Epub 2015 Jul 2.

PMID:
26143613
16.

[Ernst-Martin Lemmel on his 80th birthday].

Keitel W.

Z Rheumatol. 2015 Jun;74(5):462. doi: 10.1007/s00393-015-1617-y. German. No abstract available.

PMID:
26085077
17.

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant.

Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL.

Open Forum Infect Dis. 2014 Oct 8;1(3):ofu091. doi: 10.1093/ofid/ofu091. eCollection 2014 Dec.

18.

Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.

Winokur PL, Patel SM, Brady R, Chen WH, El-Kamary SS, Edwards K, Creech CB, Frey S, Keitel WA, Belshe R, Walter E, Bellamy A, Hill H.

J Infect Dis. 2015 Aug 15;212(4):525-30. doi: 10.1093/infdis/jiv087. Epub 2015 Feb 23.

19.

[Bulgarian rheumatology in the twentieth century : German-Bulgarian collegiality].

Keitel W, Boykinov IN, Sheitanov Y, Kolarow Z.

Z Rheumatol. 2015 Mar;74(2):159-64. doi: 10.1007/s00393-014-1519-4. German. No abstract available.

PMID:
25694237
20.

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old.

Keitel WA, Jackson LA, Edupuganti S, Winokur PL, Mulligan MJ, Thornburg NJ, Patel SM, Rouphael NG, Lai L, Bangaru S, McNeal MM, Bellamy AR, Hill HR; VTEU H3N2v Vaccine Study Work Group.

J Infect Dis. 2015 Aug 15;212(4):552-61. doi: 10.1093/infdis/jiv056. Epub 2015 Feb 3.

Supplemental Content

Loading ...
Support Center